Skip to content

Released Aug 10, 2023, after the close

10-Q filed Aug 10, 2023, 41 days after period end · 0000950170-23-041314

Q2 2023 · 10-Q
Revenue$269.00K−70.0% vs Q2 2022+20.6% vs Q1 2023
Net Income-$11.90MN/M vs Q2 2022N/M vs Q1 2023
EPS Diluted-$0.23N/M vs Q2 2022N/M vs Q1 2023
Operating Income-$12,890,000N/M
Operating Cash Flowderived-$18,564,000N/M
Margins · derived
Operating margin-4791.8%−1881.1 pt vs Q2 2022
Net margin-4423.8%−1220.7 pt vs Q2 2022

What the release said

The release

Same quarter

MetricQ2 2023Q2 2022Q2 2021Q2 2020
Revenue$269.00K$896.00K$2.11M$51.00K
Net Income-$11.90M-$28.70M-$18.60M-$17.50M
EPS Diluted-$0.23-$0.87-$0.63-$0.85

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Spero Therapeutics, Inc. · CIK 1701108 · Engraved from SEC EDGAR